Neflamapimod Receives Orphan Drug Designation by FDA for Frontotemporal Dementia

Published Date: 19 Dec 2024

Most recently reported topline data from the RewinD-LB phase 2b trial in patients with dementia with Lewy bodies showed that neflamapimod failed to meet its primary end point and secondary end points.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?

2.

DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance

3.

For patients with prostate cancer, long-term follow-up helps identify treatment side effects.

4.

Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?

5.

Chemotherapy can be a challenging treatment?here's how to deal with some of the side-effects


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot